All In Biotech

NDA 211367 · Exeltis USA INC

Slynd

Drospirenone · Oral

Last checked: Nov 19, 2026Latest source record: May 23, 2019 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

May 23, 2019

Approved uses

1

Original approval plus efficacy supplements

Registered trials

146

48 Phase 3, 7 recruiting

FAERS reports

5,416

1,061 serious, 24 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Aug 27, 2026.

SLYND is a progestin indicated for use by females of reproductive potential to prevent pregnancy. SLYND is a progestin indicated for use by females of reproductive potential to prevent pregnancy. ( 1 )

Mechanism: SLYND progestin-only oral contraceptive lowers the risk of becoming pregnant primarily by suppressing ovulation.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • May 23, 2019 Original approval · Type 2 - New Active Ingredient and Type 3 - New Dosage Form LabelLetterReview
1 products under this application
  • SLYND · DROSPIRENONE 4MG · TABLET, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Drospirenone" as an intervention, any sponsor and status, largest first.

All 146 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • intermenstrual bleeding1,691
  • amenorrhoea863
  • heavy menstrual bleeding634
  • dysmenorrhoea389
  • product dose omission issue251
  • nausea231
  • product use in unapproved indication225
  • headache201
  • intentional dose omission199
  • wrong technique in product usage process181
  • fatigue169
  • menstruation irregular162

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20052
20071
20082
20092
20108
20114
20124
20138
20142
20154
201610
20175
201820
201943
202095
2021131
2022402
2023936
20241,094
20251,316
20261,327

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Slynd (Drospirenone)

2024 spending

$2.0M

Beneficiaries

1,718

6,063 claims

Per beneficiary

$1,138

$6.86 per unit

View as table
YearSpending
2020$184,831
2021$558,398
2022$1,078,573
2023$1,865,562
2024$1,955,749

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 311 on PubMed

Sponsor: Exeltis USA INC

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.